Paper Details

  1. Home
  2. Paper Details

Spleen tyrosine kinase (Syk) inhibitor fostamatinib limits tissue damage and fibrosis in a bleomycin-induced scleroderma mouse model.

Author: AyvazSuleyman, CanGuray, DemirtasSelim, KaracaTuran, PamukGulsum Emel, PamukOmer Nuri, TsokosGeorge C

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Fostamatinib is a Syk inhibitor. This study investigated the ability of fostamatinib to protect mice from bleomycin-induced scleroderma.
Paper Details　
Original Abstract of the Article :
The pathogenesis of fibrosis in scleroderma (SSc) is unknown. TGF-β and platelet-derived growth factor are important in the development of fibrosis and tyrosine kinases are involved in these pathways. The possible antifibrotic effects of various kinase inhibitors in SSc have been studied before. Spl...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/26148346

データ提供：米国国立医学図書館（NLM）

Scleroderma: A New Path to Fighting Fibrosis

Scleroderma (SSc) is a chronic autoimmune disease that causes fibrosis, or excessive scar tissue formation, in the skin and internal organs. This study investigates the potential of fostamatinib, a Syk inhibitor, in preventing fibrosis in a mouse model of SSc. This study investigates a potential new therapeutic avenue for treating SSc, focusing on inhibiting a crucial enzyme involved in fibrosis development.

Fostamatinib: A Potential Weapon Against Fibrosis

The results of this study suggest that fostamatinib can significantly limit tissue damage and fibrosis in a mouse model of SSc. This exciting discovery opens doors to new therapeutic strategies for treating SSc, potentially leading to improved outcomes for patients.

A New Oasis in the Desert of SSc

This research offers hope for individuals with SSc who have been facing limited treatment options. It showcases the potential of targeting specific enzymes involved in fibrosis development to combat the disease. This research is like a refreshing oasis in the vast desert of SSc research.

Dr.Camel's Conclusion

Fostamatinib's potential to limit tissue damage and fibrosis in a mouse model of SSc is a promising development in the fight against this debilitating disease. This discovery is like a towering sandcastle in the desert of SSc research. It's a reminder that progress is possible even in the face of challenging conditions.

Date :
  1. Date Completed 2015-10-26
  2. Date Revised 2021-12-03
Further Info :

Pubmed ID

26148346

DOI: Digital Object Identifier

8916

Related Literature

Article Analysis
・Effects of fostamatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.